MOLECULAR/CELLULAR PREDICTORS OF BREAST CANCER PROGNOSIS

该计划项目的目标是识别分子损伤 与某些乳腺癌的侵袭性临床行为有关 将这些分子洞察力转化为预后指标。我们会 继续我们的多学科方法来理解 不同患者在细胞生物学上的根本差异 恶性上皮及其反应性间质。三个项目将 集中在肿瘤细胞的分子损伤上，而两个 项目将集中在基质上。项目1将评估 四种ETS相关转录因子的调控失调及其意义 与HER2癌基因过表达的关系项目2将克隆 乳腺癌中新发现的三个扩增片段的靶基因。这个 下一个项目将评估乳腺癌分子细胞遗传学 新开发的技术。翻译成临床相关的检测方法 将是免疫病理学核心的责任，将适用于 使用档案石蜡的玻片化验项目的发现- 嵌入的组织。对这些项目的额外支持将来自 组织累积临床核心，生物统计学和数据库核心，a 细胞生物学核心和管理核心。

The goals of this Program Project are to identify the molecular lesions associated with aggressive clinical behavior of some breast cancers and to translate these molecular insights into prognostic indicators. We will continue our multidisciplinary approach toward understanding the fundamental differences among patients in the cellular biology of the malignant epithelium and its reactive stroma. Three projects will concentrate on the molecular lesions in the tumor cells, while two projects will concentrate on the stroma. Project 1 will evaluate dysregulation of four ETS related transcription factors and their relationship to HER2 oncogene overexpression. Project 2 will clone the target genes of three newly identified amplicons in breast cancer. The next project will evaluate breast cancer molecular cytogenetics using newly developed technologies. Translation to clinically relevant assays will be the responsibility of the Immunopathology Core which will apply discoveries of the Projects to slide-based assays using archival paraffin- embedded tissues. Additional support for the Projects will come from a Clinical Core for tissue accrual, a Biostatistics and Database Core, a Cell Biology Core, and an Administrative Core.